Papillomavirus Infection and Prevention: How Much Does the Sicilian Population Know? An Observational Study
Abstract
:Highlights
- To date, incidence of HPV-related oral and oropharyngeal carcinoma is increased;
- Spread of HPV infection among youth is due to sexual precocity and promiscuity;
- Two HPV strains are primarily related to cancer onset: 16 and 18;
- There are different HPV vaccines but knowledge and adherence are still quite low;
- Not only young women must be aware on risk factors and vaccine.
Abstract
1. Introduction
2. Materials and Methods
2.1. Questionnaire
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Arbyn, M.; Weiderpass, E.; Bruni, L.; de Sanjosé, S.; Saraiya, M.; Ferlay, J.; Bray, F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health 2020, 8, e191–e203. [Google Scholar] [CrossRef]
- Saraniti, C.; Greco, G.; Verro, B.; Lazim, N.M.; Chianetta, E. Impact of Narrow Band Imaging in Pre-Operative Assessment of Suspicious Oral Cavity Lesions: A Systematic Review. Iran. J. Otorhinolaryngol. 2021, 33, 127–135. [Google Scholar] [CrossRef]
- Candotto, V.; Lauritano, D.; Nardone, M.; Baggi, L.; Arcuri, C.; Gatto, R.; Gaudio, R.M.; Spadari, F.; Carinci, F. HPV Infection in the Oral Cavity: Epidemiology, Clinical Manifestations and Relationship with Oral Cancer. Oral Implantol. 2017, 10, 209–220. [Google Scholar] [CrossRef]
- De Martel, C.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 2017, 141, 664–670. [Google Scholar] [CrossRef]
- Osazuwa-Peters, N. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States—Do we need a broader vaccine policy? Vaccine 2013, 31, 5500–5505. [Google Scholar] [CrossRef] [PubMed]
- Tagliabue, M.; Mena, M.; Maffini, F.; Gheit, T.; Blasco, B.Q.; Holzinger, D.; Tous, S.; Scelsi, D.; Riva, D.; Grosso, E.; et al. Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. Cancers 2020, 12, 3567. [Google Scholar] [CrossRef] [PubMed]
- Del Mistro, A.; Frayle, H.; Menegaldo, A.; Favaretto, N.; Gori, S.; Nicolai, P.; Spinato, G.; Romeo, S.; Tirelli, G.; Da Mosto, M.C.; et al. Age-independent increasing prevalence of Human Papillomavirus-driven oropharyngeal carcinomas in North-East Italy. Sci. Rep. 2020, 10, 9320. [Google Scholar] [CrossRef] [PubMed]
- Clair, J.M.-S.; Alani, M.; Wang, M.B.; Srivatsan, E.S. Human papillomavirus in oropharyngeal cancer: The changing face of a disease. Biochim. Biophys. Acta 2016, 1866, 141–150. [Google Scholar] [CrossRef]
- Castle, P.E.; Maza, M. Prophylactic HPV vaccination: Past, present, and future. Epidemiol. Infect. 2016, 144, 449–468. [Google Scholar] [CrossRef]
- Sawaya, G.F.; Smith-McCune, K.; Kuppermann, M. Cervical Cancer Screening: More Choices in 2019. JAMA 2019, 321, 2018–2019. [Google Scholar] [CrossRef] [PubMed]
- Guan, P.; Howell-Jones, R.; Li, N.; Bruni, L.; De Sanjosé, S.; Franceschi, S.; Clifford, G.M. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131, 2349–2359. [Google Scholar] [CrossRef] [PubMed]
- Rapado-González, Ó.; Martínez-Reglero, C.; Salgado-Barreira, Á.; Rodríguez-Fernández, A.; Aguín-Losada, S.; León-Mateos, L.; Muinelo-Romay, L.; López-López, R.; Suarez-Cunqueiro, M.M. Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis. J. Clin. Med. 2020, 9, 1305. [Google Scholar] [CrossRef] [PubMed]
- Ndiaye, C.; Mena, M.; Alemany, L. Correction to Lancet Oncol 2014; 15: 1324. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol. 2015, 16, e262. [Google Scholar] [CrossRef] [PubMed]
- Petrusek, J.; Thorpe, E.; Britt, C.J. HPV vaccination practices and attitudes among primary care physicians since FDA approval to age 45. Am. J. Otolaryngol. 2020, 41, 102685. [Google Scholar] [CrossRef] [PubMed]
- Food and Drug Administration (FDA). FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 through 45 Years Old. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old (accessed on 5 October 2018).
- Centers for Disease Control and Prevention. Vaccinating Boys and Girls. Update 15 August 2019. Available online: https://www.cdc.gov/hpv/parents/vaccine.html (accessed on 23 June 2020).
- Harrison, S.E.; Yelverton, V.; Wang, Y.; Ostermann, J.; Fish, L.J.; Williams, C.L.; Vasudevan, L.; Walter, E.B. Examining Associations between Knowledge and Vaccine Uptake Using the Human Papillomavirus Knowledge Questionnaire (HPV-KQ). Am. J. Health Behav. 2021, 45, 810–827. [Google Scholar] [CrossRef]
- Fishman, J.; Taylor, L.; Kooker, P.; Frank, I. Parent and Adolescent Knowledge of HPV and Subsequent Vaccination. Pediatrics 2014, 134, e1049–e1056. [Google Scholar] [CrossRef]
- Kasymova, S.; E Harrison, S.; Pascal, C. Knowledge and Awareness of Human Papillomavirus Among College Students in South Carolina. Infect. Dis. Res. Treat. 2019, 12, 1178633718825077. [Google Scholar] [CrossRef]
- Barnard, M.; George, P.; Perryman, M.L.; Wolff, L.A. Human papillomavirus (HPV) vaccine knowledge, attitudes, and uptake in college students: Implications from the Precaution Adoption Process Model. PLoS ONE 2017, 12, e0182266. [Google Scholar] [CrossRef]
- Istituto Nazionale di Statistica (Instat). II Censimento Permanente della Popolazione in Sicilia. 2020. Available online: https://www.istat.it/it/files//2022/03/Il-Censimento-della-popolazione-in-Sicilia_focus.pdf (accessed on 16 March 2022).
- Radzki, D.; Kusiak, A.; Ordyniec-Kwaśnica, I.; Bondarczuk, A. Human papillomavirus and leukoplakia of the oral cavity: A systematic review. Adv. Dermatol. Allergol. 2022, 39, 594–600. [Google Scholar] [CrossRef]
- Bishop, J.A.; Lewis, J.S.; Rocco, J.W.; Faquin, W.C. HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. Semin. Diagn. Pathol. 2015, 32, 344–351. [Google Scholar] [CrossRef]
- Hübbers, C.U.; Akgül, B. HPV and cancer of the oral cavity. Virulence 2015, 6, 244–248. [Google Scholar] [CrossRef] [PubMed]
- Osazuwa-Peters, N.; Boakye, E.A.; Mohammed, K.A.; Tobo, B.B.; Geneus, C.J.; Schootman, M. Not just a woman’s business! Understanding men and women’s knowledge of HPV, the HPV vaccine, and HPV-associated cancers. Prev. Med. 2017, 99, 299–304. [Google Scholar] [CrossRef] [PubMed]
- Breitkopf, C.R.; Rutten, L.J.F.; Findley, V.; Jacobson, D.J.; Wilson, P.M.; Albertie, M.; Jacobson, R.M.; Colón-Otero, G. Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population. Cancer Med. 2016, 5, 3346–3352. [Google Scholar] [CrossRef]
- Dayyani, F.; Etzel, C.J.; Liu, M.; Ho, C.-H.; Lippman, S.M.; Tsao, A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010, 2, 15. [Google Scholar] [CrossRef] [PubMed]
- Saraniti, C.; Montana, F.; Chianetta, E.; Greco, G.; Verro, B. Impact of resection margin status and revision transoral laser microsurgery in early glottic cancer: Analysis of organ preservation and local disease control on a cohort of 153 patients. Braz. J. Otorhinolaryngol. 2020, 17, S1808-8694(20)30174-9. [Google Scholar] [CrossRef]
- Pytynia, K.B.; Dahlstrom, K.R.; Sturgis, E.M. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014, 50, 380–386. [Google Scholar] [CrossRef]
- Yakin, M.; Seo, B.; Hussaini, H.; Rich, A.; Hunter, K. Human papillomavirus and oral and oropharyngeal carcinoma: The essentials. Aust. Dent. J. 2018, 64, 11–18. [Google Scholar] [CrossRef]
- Saraniti, C.; Gallina, S.; Verro, B. NBI and Laryngeal Papillomatosis: A Diagnostic Challenge: A Systematic Review. Int. J. Environ. Res. Public Health 2022, 19, 8716. [Google Scholar] [CrossRef]
- Cheng, L.; Wang, Y.; Du, J. Human Papillomavirus Vaccines: An Updated Review. Vaccines 2020, 8, 391. [Google Scholar] [CrossRef]
- Zhou, J.Z.; Jou, J.; Cohen, E. Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. Cancers 2021, 14, 33. [Google Scholar] [CrossRef]
- De Sanjosé, S.; Brotons, M.; Pavón, M.A. The natural history of human papillomavirus infection. Best Pr. Res. Clin. Obstet. Gynaecol. 2018, 47, 2–13. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, K.; Jakobsen, K.; Jensen, J.; Grønhøj, C.; Von Buchwald, C. The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection—A Systematic Review. Viruses 2021, 13, 1339. [Google Scholar] [CrossRef] [PubMed]
- Fakhry, C.; Westra, W.H.; Wang, S.J.; Van Zante, A.; Zhang, Y.; Rettig, E.; Yin, L.; Ryan, W.R.; Ha, P.K.; Wentz, A.; et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 2017, 123, 1566–1575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Items | Multiple Answers | N° (%) | |
---|---|---|---|
| Female | 514 (60.90) | |
Male | 330 (30.10) | ||
| 18–20 yo | 39 (4.62) | |
21–30 yo | 452 (53.55) | Female: 300 (66.37 Male: 152 (33.63) | |
31–40 yo | 144 (17.06) | ||
41–50 yo | 92 (10.90) | ||
51–60 yo | 88 (10.43) | ||
>61 yo | 29 (3.44) | ||
| Province of Agrigento | 96 (11.37) | |
Province of Caltanissetta | 91 (10.90) | ||
Province of Catania | 92 (10.90) | ||
Province of Enna | 84 (9.95) | ||
Province of Messina | 83 (.84) | ||
Province of Palermo | 100 (11.85) | ||
Province of Ragusa | 86 (10.19) | ||
Province of Siracusa | 108 (12.80) | ||
Province of Trapani | 104 (12.32) | ||
| Yes | 813 (96.33) | Female: 752 (92.50) |
Male: 61 (7.50) 18–20 yo: 36 (4.43) 21–30 yo: 444 (54.61) 31–40 yo: 140 (17.22) 41–50 yo: 89 (10.95) 51–60 yo: 81 (9.96) >61 yo: 23 (2.83) Siracusa *: 105 (12.91) Trapani *: 103 (12.67) | |||
No | 31 (3.67) | Female: 22 (70.97) Male: 9 (29.03) 18–20 yo: 3 (9.68) 21–30 yo: 8 (25.81) 31–40 yo: 4(12.90) 41–50 yo: 3 (9.68) 51–60 yo: 7 (22.58) >61 yo: 6 (19.35) Palermo *: 10 (32.26) | |
| Yes | 787 (88.51) | Female: 469 (62.78) Male: 278 (37.22) |
No | 86 (10.19) | Female: 39 (45.35) Male: 47 (54.65) | |
No answer | 11 (1.30) | ||
| Yes | 416 (49.29) | Female: 268 (64.42) Male: 148 (35.58) |
No | 415 (49.17) | Female: 239 (57.59) Male: 176 (42.41) | |
No answer | 13 (1.54) | ||
| Female | 194 (22.98) | Female: 179 (92.27) Male: 15 (7.73) 18–20 yo: 10 (5.15) 21–30 yo: 91 (46.91) 31–40 yo: 32 (16.50) 41–50 yo: 27 (13.92) 51–60 yo: 26 (13.40) >61 yo: 8 (4.12) Agrigento *: 28 (14.43) |
Both | 634 (75.12) | Female: 582 (91.80) Male: 52 (8.20) 18–20 yo: 26 (4.10) 21–30 yo: 355 (55.99) 31–40 yo: 111 (17.51) 41–50 yo: 63 (9.94) 51–60 yo: 59 (9.31) >61 yo: 20 (3.15) Siracusa *: 83 (13.09) | |
No answer | 16 (1.90) | ||
| Yes | 729 (86.37) | Female: 465 (63.79) Male: 264 (36.21) |
No | 95 (11.26) | Female: 39 (41.05) Male: 56 (58.95) | |
No answer | 20 (2.37) | ||
| Female | 335 (39.69) | Female: 201 (60.00) Male: 134 (40.00) 18–20 yo: 13 (3.88) 21–30 yo: 182 (54.33) 31–40 yo: 64 (19.11) 41–50 yo: 33 (9.85) 51–60 yo: 32 (9.55) >61 yo: 11 (3.28) Trapani *: 44 (13.13) |
Male | 1 (0.12) | Female: 1 (100) 31–40 yo: 1 (100) | |
Both | 486 (57.58) | Female: 300 (61.73) Male: 186 (38.27) 18–20 yo: 23 (4.73) 21–30 yo: 259 (53.29) 31–40 yo: 77 (15.84) 41–50 yo: 57 (11.73) 51–60 yo: 53 (10.91) >61 yo: 17 (3.50) Siracusa *: 68 (13.99) Palermo *: 61 (12.55) | |
| Yes | 289 (34.24) | Female: 202 (69.90) Male: 87 (30.01) 18–20 yo: 26 (9.00) 21–30 yo: 234 (80.97) 31–40 yo: 23 (7.96) 41–50 yo: 2 (0.69) 51–60 yo: 3 (1.04) >61 yo: 1 (0.34) Trapani *: 48 (16.81) |
No and I do not want to get vaccinated | 167 (19.79) | Female: 79 (47.30) Male: 88 (52.70) 18–20 yo: 3 (1.79) 21–30 yo: 44 (26.35) 31–40 yo: 25 (14.97) 41–50 yo: 32 (19.16) 51–60 yo: 44 (26.35) >61 yo: 19 (11.38) Palermo *: 38 (22.75) | |
No but I would like to get vaccinated | 355 (42.06) | Female: 214 (60.28) Male: 141 (39.72) 18–20 yo: 6 (1.69) 21–30 yo: 158 (44.51) 31–40 yo: 92 (25.92) 41–50 yo: 54 (15.21) 51–60 yo: 37 (10.42) >61 yo: 8 (2.25) Palermo *: 49 (13.80) | |
No answer | 33 (3.91) | ||
TOTAL | 844 (100) |
Question | Odd | Chi-Squared (X2) | p-Value |
---|---|---|---|
#4 Do you know that papillomavirus infection exists? | 1.1333 | 2.6739 | 0.1020 |
#5 Do you know that papillomavirus can cause uterine cancer? | 1.2051 | 9.5958 | 0.001950 |
#6 Do you know that papillomavirus can cause cancer of the oral cavity (tonsil, palate, and tongue)? | 0.7364 | 4.0813 | 0.04336 |
#7 In your opinion, papillomavirus can affect: | 0.6441 | 0.01047 | 0.9185 |
#8 Do you know that there is a vaccine against papillomavirus? | 1.4359 | 17.7669 | 0.00002497 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Verro, B.; Gallina, S.; Saraniti, C. Papillomavirus Infection and Prevention: How Much Does the Sicilian Population Know? An Observational Study. Int. J. Environ. Res. Public Health 2022, 19, 11032. https://doi.org/10.3390/ijerph191711032
Verro B, Gallina S, Saraniti C. Papillomavirus Infection and Prevention: How Much Does the Sicilian Population Know? An Observational Study. International Journal of Environmental Research and Public Health. 2022; 19(17):11032. https://doi.org/10.3390/ijerph191711032
Chicago/Turabian StyleVerro, Barbara, Salvatore Gallina, and Carmelo Saraniti. 2022. "Papillomavirus Infection and Prevention: How Much Does the Sicilian Population Know? An Observational Study" International Journal of Environmental Research and Public Health 19, no. 17: 11032. https://doi.org/10.3390/ijerph191711032